US equities |
NVDA $186.64 ▲+2.78% MU $690.00 ▲+5.12% AMD $449.04 ▲+11.04% SPCX $134.27 ▲+8.62% AAPL $342.37 ▼-0.52% SNDK $835.06 ▲+3.55% MSFT $530.61 ▼-0.99% TSLA $358.22 ▲+4.23%
FinancialContent

Profound Medical Corp. - common stock (NQ:PROF)

7.210 +0.330 (+4.80%)
Delayed Quote Updated: 4:00 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Profound Medical Corp. - common stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Incision-Free, MRI-Guided Prostate Treatment with Profound’s TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone
From Profound Medical Corp.
Via GlobeNewswire
News headline image
CAPTAIN Trial Comparing Profound’s MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 13, 2025 ↗
 
Via Benzinga
News headline image
Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24
From Profound Medical Corp.
Via GlobeNewswire
Here are the top movers in Friday's session. ↗
Via Chartmill
News headline image
Profound Medical Reports Fourth Quarter and Full Year 2025 Financial Results
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th – Conference Call to Follow
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Honored with INOVAIT’s 2025–2026 Mount Logan Award Recognizing the TULSA Procedure™ for Prostate Disease
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Announces Upcoming Investor Events
From Profound Medical Corp.
Via GlobeNewswire
News headline image
PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to Incision-Free Care for Women’s Health
Milestone reflects accelerating adoption of innovative, non-surgical treatment options for uterine conditions 
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Mount Sinai Becomes First in Metro New York to Deliver Incision-Free, MRI-Guided Prostate Treatment with TULSA-PRO®
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Surpasses 2025 TULSA-PRO® Installed Base Goal
Company’s year-end TULSA-PRO installed base stood at 78 systems; qualified sales pipeline grew to 97 new systems 
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Johns Hopkins Medicine Treats First Commercial TULSA-PRO® Case
Profound Medical marks major milestone as the hospital launches its state-of-the-art iMRI suite to expand access to advanced prostate care 
From Profound Medical Corp.
Via GlobeNewswire
InvestorNewsBreaks – Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) Closes $36 Million Registered Direct Offering
Via Investor Brand Network
News headline image
Profound Medical Corp. Announces Closing of Private Placement
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Corp. Announces Upsize of Private Placement
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Corp. Closes $36 Million Registered Direct Offering; Expects to Complete Subsequent Private Placement On or Before December 30th
Financing included participation by healthcare-dedicated investors alongside existing shareholders 
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement
Financing included participation by healthcare-dedicated investors alongside existing shareholders 
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Reports Strong Third Quarter 2025 Financial Results
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Announces Strategic Distribution Agreement with Getz Healthcare to Bring TULSA-PRO® to Australia and New Zealand
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Stanford Medicine’s Dr. Pejman Ghanouni Receives RSNA’s Cum Laude Award for CAPTAIN Perioperative Data Presentation
– CAPTAIN is the first randomized controlled trial ever comparing a new technology to the standard of care of robotic radical prostatectomy to successfully recruit to target – 
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Inks Exclusive Distribution Agreement for TULSA-PRO® and Sonalleve® with Al Faisaliah Medical Systems in Saudi Arabia
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings
New BPH module and clinical data reinforce the TULSA Procedure™’s versatility in prostate disease, superior patient benefits, and potential for mainstream adoption 
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Regains Exclusive Distribution Rights for TULSA-PRO® in Canada from Knight
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Celebrates The Hong Center’s 200th Independent TULSA Procedure for Prostate Disease
Renowned urologist Dr. Mark Hong sets new global benchmark for urologist-led, MRI-guided prostate treatment, leading a growing movement toward incision-free prostate therapy 
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical to Participate in the Stifel 2025 Healthcare Conference
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Congratulates the Busch Center for Achieving 500th TULSA Procedure Milestone
Clinical validation from the Busch Center highlights the proven, scalable innovation driving a paradigm shift in prostate care — delivering precision treatment and better patient outcomes 
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third Quarter
To release full third quarter 2025 financial results on November 13th; conference call to follow 
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Texas Prostate and Dallas Medical Center Launch First-of-its-Kind TULSA Program, Expanding Access to Advanced Prostate Treatment
New program delivers TULSA Procedure’s precision treatment - minimal side effects, no overnight hospital stay – to Medicare patients across Texas 
From Profound Medical Corp.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >